
BYSI
Beyondspring Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.245
Open
2.200
VWAP
2.18
Vol
12.77K
Mkt Cap
87.89M
Low
2.160
Amount
27.83K
EV/EBITDA(TTM)
--
Total Shares
40.30M
EV
95.00M
EV/OCF(TTM)
--
P/S(TTM)
--
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Show More
Valuation Metrics
The current forward P/E ratio for Beyondspring Inc (BYSI.O) is -6.88, compared to its 5-year average forward P/E of -3.24. For a more detailed relative valuation and DCF analysis to assess Beyondspring Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.24
Current PE
-6.88
Overvalued PE
-0.91
Undervalued PE
-5.57
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-1.63
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.89
Undervalued EV/EBITDA
-4.16
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
32.64
Current PS
0.44
Overvalued PS
84.51
Undervalued PS
-19.24
Financials
Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
-2.61M
Operating Profit
FY2025Q1
-2.58M
Net Income after Tax
FY2025Q1
0.11
EPS - Diluted
FY2025Q1
-4.25M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BYSI News & Events
Events Timeline
2025-07-07 (ET)
2025-07-07
07:15:43
BeyondSpring announces publication of human clinical study on plinabulin

2025-06-03 (ET)
2025-06-03
07:04:00
BeyondSpring presents interim phase 2 data on 303 study

2025-03-27 (ET)
2025-03-27
07:11:56
BeyondSpring announces expected 2025 milestones

Sign Up For More Events
Sign Up For More Events
News
9.0
06-03NewsfilterBeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
9.0
05-12NASDAQ.COMBeyondSpring Inc. Reports Positive Early Results for Plinabulin in Metastatic Cancer and Updates on SEED Therapeutics' Progress
9.5
05-12NewsfilterBeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
Sign Up For More News
People Also Watch

NB
NioCorp Developments Ltd
3.165
USD
-1.09%

RMTI
Rockwell Medical Inc
1.100
USD
+0.92%

MGLD
Marygold Companies Inc
0.870
USD
-0.46%

ANVS
Annovis Bio Inc
2.650
USD
-5.69%

OAKU
Oak Woods Acquisition Corp
11.910
USD
-0.42%

ICCM
Icecure Medical Ltd
1.020
USD
+0.99%

PRE
Prenetics Global Ltd
7.910
USD
-1.86%

CULP
Culp Inc
4.440
USD
-0.22%

GNTA
Genenta Science SPA
3.770
USD
-0.26%

FFIE
Faraday Future Intelligent Electric Inc
0
USD
+8.97%
FAQ

What is Beyondspring Inc (BYSI) stock price today?
The current price of BYSI is 2.18 USD — it has decreased -0.91 % in the last trading day.

What is Beyondspring Inc (BYSI)'s business?

What is the price predicton of BYSI Stock?

What is Beyondspring Inc (BYSI)'s revenue for the last quarter?

What is Beyondspring Inc (BYSI)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Beyondspring Inc (BYSI)'s fundamentals?

How many employees does Beyondspring Inc (BYSI). have?
